Home | Products | Profile | Trends | International Cooperation | Communication&Feedback | 中文   
President`s oration
Research center
Quality certification

Changchun Changsheng Life Sciences Ltd. was established on August 18, 1992 and is a state-level high-tech enterprise engaged in the research and development, production and sales of vaccines for human use. Adhering to the development purpose of Caring Life and Seeding Health, Changsheng has been working hard to develop and manufacture preventive biological product at First-class Level both at Home and Abroad, providing prevention and protection for life and health of the public. Leaders of the Party and the nation, such as Hu Jintao, Jiang Zemin, Zhang Dejiang, Gu Mu and Zou Jiahua, inspected the company successively and gave the highest praise to its achievements and development direction.

Changchun Changsheng is located in Changchun City, a north Spring city in Jilin Province in China. It covers an area of 70,000 square meters and has a R&D center of more than 5,500 square meters and a modern vaccine production base over 35,000 square meters complying with the latest GMP standards. Under the leadership of CEO Gao Junfang, the company has implemented the development strategy of Market Oriented, with Innovation as soul, Information as Carrier and Survival on Quality. After more than 20 years'''''''''''''''' development, the company has owned Hepatitis A (Live) Vaccine,Freeze-dried; Rabies Vaccine (Vero cell) for Human Use, Freeze-dried; Influenza Vaccine (Split Virion), Inactivated; Varicella Vaccine, Live; Diphtheria,Tetanus Acellular Pertussis Combined Vaccine, Adsorbed; Group ACYW135 Meningococcal Polysaccharide Vaccine and so on, which is one of the private-owned enterprises with most abundant vaccines products in the country. In recent years, the company has stepped into the fast lane whose assets and profit indicators maintain rapid growth. By the end of 2016, the total assets of the company were over 600 million USD, the net assets about 541 million USD, the market capitalization more than 256 million USD with 1,000 employees above.


Changchun Changsheng always insists technological breakthrough and innovation, cultivated an expert R&D team, built three R&D platforms for bacterial vaccine, viral vaccine and gene engineering product, mastered industrial leading technology, obtained a series of technological achievements and won 13 patents for innovation. The company is the first batch of vaccine enterprises in China to independently develop and sell Influenza Vaccine and Rabies Vaccine for Human Use (Vero cell), one of domestic enterprises which produce viral and bacterial vaccine at the same time and a vaccine enterprise which is firstly approved to produce Hepatitis A (Live) Vaccine with cell factory technology in China. At present, the company has developed and stored a product echelon conforming to the industrial trend with broad market prospect. Clinical research of Herpes Zoster Vaccine and Influenza Vaccine, Inactivated (quadrivalent) has been carried out. Other newly developed vaccines have made significant progresses, such as 23-valent pneumococcal polysaccharide vaccine, multivalent conjugate vaccine, pertussis component vaccine, etc. In May 2010, the company, together with Japan GTS Company, cooperated to develop adalimumab biosimilar drug titled King of Medicine and marched into the monoclonal antibody biological product field, further expanding the product field.

Changchun Changsheng always regards product quality as the lifeline for the survival and development and sets up a triple protective system: quality control, safe production and environmental protection, continuously optimizing its production process and committing itself to providing high-quality vaccines to the masses. The company pioneers the use of Varicella Vaccine, Live free of human albumin and gelatin and obtains exclusive approval of a two-dose immunization program for 1 to 12-year-old children; uses a unique lyophilization stabilizer for Rabies Vaccine;  accesses to national invention patent for purification technology of Influenza Vaccine; applies industry-leading detoxification process to DTAP manufacture. It is the advanced production technology that ensures better vaccine stability, reduces adverse reactions and lowers potential risks, laying solid foundation for its products to be in the forefront of the industry, all types of products to occupy the market share, and keep brand reputation and market influence.

Changchun Changsheng Life Sciences Ltd. actively constructed domestic integration service network, covering all provinces, autonomous regions and direct-controlled municipality except Tibet and Hong Kong, Macao and Taiwan. By virtue of its best quality,Changsheng implements regional penetration strategy to international market and successfully established vaccine export cooperation relationship with over 20 countries and regions in Asia, Europe, Africa, North America, etc., becoming one of the important enterprises exporting large biological products in domestic and receiving wide praise from international cooperative partners.

On December 6, 2015, through asset restructuring, Changchun Changsheng Company was listed in Shenzhen Stock Exchange (stock abbreviation: Changsheng Shengwu, stock code: 002680). In future, the company will energetically promote acquisition and reorganization and build Industry+Capital two wheel drive strategic development pattern fully relying on the capital market platform and surrounding closely massive health industry and constantly expand the company pharmacy development field, enrich product line, gradually establish systemic medicine industry platform integrating precaution, treatment and rehabilitation, constantly improve enterprise core competence and strive to create an innovative high-end medical science and technology enterprise with preventative biological products as the core.

Copyright@2005-2008 ChangSheng Inc. All rights reserved 长生集团 版权所有
吉ICP 05001828 电信业务经营许可证00-0000004